Sugarloaf Wealth Management’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-1
| Closed | – | – | 691 |
|
|
2024
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 722 |
|
|
2023
Q4 | $1 | Hold |
1
| – | – | ﹤0.01% | 683 |
|
|
2023
Q3 | $1 | Hold |
1
| – | – | ﹤0.01% | 681 |
|
|
2023
Q2 | $1 | Hold |
1
| – | – | ﹤0.01% | 691 |
|
|
2023
Q1 | $1 | Hold |
1
| – | – | ﹤0.01% | 702 |
|
|
2022
Q4 | $2 | Hold |
1
| – | – | ﹤0.01% | 784 |
|
|
2022
Q3 | $1K | Hold |
1
| – | – | ﹤0.01% | 827 |
|
|
2022
Q2 | $0 | Buy |
+1
| New | +$5 | ﹤0.01% | 855 |
|
|
2022
Q1 | – | Hold |
0
| – | – | – | 788 |
|
|
2021
Q4 | – | Hold |
0
| – | – | – | 801 |
|
|
2021
Q3 | – | Hold |
0
| – | – | – | 824 |
|
|
2021
Q2 | – | Hold |
0
| – | – | – | 801 |
|
|
2021
Q1 | – | Hold |
0
| – | – | – | 806 |
|
|
2020
Q4 | – | Hold |
0
| – | – | – | 776 |
|
|
2020
Q3 | – | Hold |
0
| – | – | – | 751 |
|
|
2020
Q2 | – | Hold |
0
| – | – | – | 757 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 769 |
|
Sugarloaf Wealth Management's NVIV Position: Q2 2024 in Review
Sugarloaf Wealth Management sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q2 2024, closing a stake of 1 share.
Sugarloaf Wealth Management first reported a position in NVIV in Q2 2022 and held it in 8 quarters. The position peaked at $1K in Q3 2022. 0 funds tracked by Wall St. Rank hold NVIV as of Q2 2024.
- Sugarloaf Wealth Management reported no remaining InVivo Therapeutics Holdings Corp position as of Q2 2024 after selling out during the quarter.
- Sugarloaf Wealth Management sold 1 InVivo Therapeutics Holdings Corp share in Q2 2024.
- Sugarloaf Wealth Management first reported a position in InVivo Therapeutics Holdings Corp in Q2 2022 and held it in 8 quarters.
- Sugarloaf Wealth Management's InVivo Therapeutics Holdings Corp position peaked at $1K in Q3 2022.
- 0 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q2 2024.
Based on Sugarloaf Wealth Management's 13F filing for Q2 2024, filed 8 Jul 2024.